Steris (STE) International Revenue Performance Explored

Explore Steris' (STE) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Zacks Investment Research • Feb 9, 2026

STERIS: A Bump In The Road For A Reliable Name

STERIS offers a resilient, high-quality business model with some premium valuation, benefiting from hard-to-replicate sterilization networks and stable healthcare procedure volumes. Recent quarterly results included on-target 8% organic revenue growth but margin pressure from tariffs, with management raising tariff impact guidance by $10 million. STE stands to gain from stricter ethylene oxide (EtO) regulations, as compliance costs favor large, established players and will drive more outsourcing to its facilities.

Seeking Alpha • Feb 6, 2026

STERIS plc (STE) Q3 2026 Earnings Call Transcript

STERIS plc (STE) Q3 2026 Earnings Call Transcript

Seeking Alpha • Feb 5, 2026

STE Q3 Earnings Meet, Revenues Beat, Stock Dips in Aftermarket Trading

STERIS shares slide after hours as Q3 earnings meet estimates and revenues beat, with investors focused on gross margin contraction despite solid growth.

Zacks Investment Research • Feb 5, 2026

STERIS Announces Financial Results for Fiscal 2026 Third Quarter

Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53 Fiscal 2026 outlook maintained DUBLIN, IRELAND, Feb. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $1.5 billion compared with $1.4 billion in the third quarter of fiscal 2025.

GlobeNewsWire • Feb 4, 2026

Steris (STE) Meets Q3 Earnings Estimates

Steris (STE) came out with quarterly earnings of $2.53 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $2.32 per share a year ago.

Zacks Investment Research • Feb 4, 2026

Compared to Estimates, Steris (STE) Q3 Earnings: A Look at Key Metrics

The headline numbers for Steris (STE) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Feb 5, 2026

STERIS Announces Dividend of $0.63 per share

DUBLIN, IRELAND, Jan. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on March 19, 2026, to shareholders of record at the close of business on February 17, 2026.

GlobeNewsWire • Jan 28, 2026

STERIS' Q3 Earnings on Deck: What's in Store for the Stock?

STE enters Q3 earnings with revenues seen up 8% to $1.48B and EPS rising 9.1% to $2.53, supported by strength in Healthcare, AST and Life Sciences.

Zacks Investment Research • Jan 28, 2026

STERIS to Host a Conference Call for Fiscal 2026 Third Quarter Results on February 5, 2026

DUBLIN, IRELAND, Jan. 21, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2026 third quarter results at 9:00 a.m. ET on February 5, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.

GlobeNewsWire • Jan 21, 2026